COVID-19 Hits Sales Of Biogen Biosimilars Portfolio
As Firm Eyes Tecfidera US Landscape
Biogen received a bump to biosimilar earnings in the first quarter of this year, but this reversed in Q2 with fewer new patients venturing out to begin treatment on its portfolio of chronic treatment options. Management addressed the numbers, as well as Mylan’s recent victory over its Tecfidera intellectual property in the US.
